Zangmeister Cancer Center Becomes Affiliate of Ohio State University’s James Cancer Network, Expanding Access to Exceptional Community-Based Cancer Care Across Central Ohio

Rhea-AI Summary

Zangmeister Cancer Center, a partner of American Oncology Network (NASDAQ:AONC), has become an affiliate of Ohio State’s OSUCCC – James through The James Cancer Network. The collaboration expands community-based cancer care across central Ohio, including access to more than 500 clinical trials and advanced therapies.

Patients gain local access to subspecialized oncology and hematology expertise, CAR T-cell therapy, stem cell transplant evaluation, tumor-infiltrating lymphocyte (TIL) therapy and proton therapy at OSUCCC – James, while maintaining strong ties to community care teams.

Positive

• Affiliation gives patients access to more than 500 clinical trials
• Expanded access to advanced therapies including CAR T-cell and TIL therapy
• Strengthens community-based oncology with academic subspecialty expertise in central Ohio
• Supports coordinated community outreach and expanded medical education for care teams

Negative

• None.

Market Context

This announcement highlights an affiliation that connects Zangmeister Cancer Center and American Onc...

Analysis

This announcement highlights an affiliation that connects Zangmeister Cancer Center and American Oncology Network patients with OSUCCC – James, expanding access to more than 500 clinical trials and advanced modalities such as CAR T-cell and proton therapy. It follows a series of partnerships and physician additions that broadened AON’s community footprint. Investors may watch for updates on patient volumes, referral patterns, and the practical uptake of these advanced treatment options across the network.

Key Figures

Clinical trials access: more than 500 clinical trials Network affiliates: 8 James Cancer Network affiliates

2 metrics

Clinical trials access more than 500 clinical trials Through OSUCCC – James and The James Cancer Network

Network affiliates 8 James Cancer Network affiliates Affiliates across Ohio linked to OSUCCC – James

Historical Context

5 past events · Latest: Apr 30 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 30	Physician addition	Positive	+2.8%	New experienced oncologist joined MidAmerica Cancer Care under AONC umbrella.
Apr 22	Conference participation	Positive	+16.1%	AON leadership featured in 11 sessions at oncology conference.
Mar 05	Practice partnership	Positive	-7.3%	Oncology Consultants joined AON with 18 locations and expanded resources.
Feb 04	New state entry	Positive	+4.3%	RKV Medical Center became AON’s first partner practice in Oklahoma.
Feb 03	Physician addition	Positive	+4.3%	Dr. Amy Braden joined Hematology Oncology of Indiana under AONC.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Most prior partnership and growth announcements saw positive price reactions, with one notable divergence on expansion news.

Recent Company History

Over the last few months, American Oncology Network has repeatedly highlighted growth in community-based oncology. On Feb 3 and Feb 4, 2026, it added new physicians and a first Oklahoma partner, both followed by 4.35% gains. The March 5 Oncology Consultants partnership brought a -7.33% move despite expansion. An April conference participation headline coincided with a 16.13% rise. Today’s OSUCC–James affiliation continues this strategy of broadening access to advanced therapies and clinical trials.

Key Terms

car t-cell therapy, stem cell transplant, tumor-infiltrating lymphocyte (til) therapy, proton therapy, +1 more

5 terms

car t-cell therapy medical

"including access to clinical trials, CAR T-cell therapy, stem cell transplant"

Car T-cell therapy is a medical treatment that uses a patient’s own immune cells, modified in a lab to better recognize and attack cancer cells. It is considered a breakthrough because it offers potentially long-lasting effects for certain types of cancer. For investors, its development and approval can signal advances in healthcare innovation and potential growth opportunities in the biotech sector.

stem cell transplant medical

"including access to clinical trials, CAR T-cell therapy, stem cell transplant evaluation"

A stem cell transplant is a medical procedure that replaces a person’s damaged or diseased blood- and immune-system cells with healthy stem cells from the patient or a donor, allowing the body to rebuild blood and immune function. For investors it matters because success, safety, cost and regulatory approval of transplants and related drugs, devices or donor services can shape market demand, company valuations and long-term revenue prospects—think of it as rebooting a failing system that can restore health and unlock new markets.

tumor-infiltrating lymphocyte (til) therapy medical

"including CAR T-cell therapy, tumor-infiltrating lymphocyte (TIL) therapy and proton therapy"

Tumor-infiltrating lymphocyte (TIL) therapy is a type of immunotherapy that harvests a patient’s own immune cells found inside a tumor, grows and activates them in the lab, then returns them to the patient to help fight cancer. Think of it as boosting and retraining a patient’s local tumor-fighting cells like tuning and amplifying a home security system. Investors watch TIL therapy because clinical trial results, manufacturing complexity, and regulatory approval determine its commercial potential and company value.

proton therapy medical

"including CAR T-cell therapy, tumor-infiltrating lymphocyte (TIL) therapy and proton therapy"

A cancer treatment that uses a beam of charged particles (protons) to deliver radiation precisely to a tumor while limiting damage to surrounding healthy tissue; think of it as a GPS-guided beam that stops where the tumor is instead of blasting through everything. It matters to investors because proton therapy requires very expensive equipment, long-term facility investment and depends on clinical outcomes and insurance reimbursement to generate revenue, so advances in effectiveness, cost or access can materially affect providers' financial prospects.

clinical trials medical

"Providing access to more than 500 clinical trials Providing expert oncology"

Clinical trials are carefully controlled studies that test whether a new drug, device or treatment is safe and effective in people, moving through successive stages that increase the number of participants and the rigor of testing. Investors care because trial outcomes determine whether a product can be approved and sold, shaping a company’s future revenue, valuation and risk profile—think of it as proof-of-concept testing that decides if a prototype becomes a market-ready product.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

COLUMBUS, Ohio, May 21, 2026 (GLOBE NEWSWIRE) -- Zangmeister Cancer Center, a partner practice of American Oncology Network (AON), is now an affiliate of The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) through The James Cancer Network. The affiliation expands access to exceptional cancer care across central Ohio, strengthening community-based oncology services while increasing access to academic expertise and advanced therapies.

Rooted in a shared commitment to expanding access to high-quality cancer care, the affiliation enhances local access to academic excellence by connecting community-based care with the subspecialized expertise of one of the nation’s leading comprehensive cancer centers.

Together, Zangmeister Cancer Center and The James Cancer Network are advancing community oncology care by:

• Expanding timely access to leading-edge treatments
• Providing access to more than 500 clinical trials
• Providing expert oncology and hematology care
• Increasing availability of advanced and targeted therapies

“Stronger collaboration between community oncology and academic medicine benefits the entire community,” said W. Kimryn Rathmell, MD, PhD, director of The Ohio State University Comprehensive Cancer Center and CEO of the James Cancer Hospital and Solove Research Institute. “This affiliation expands access to clinical trials and the most advanced therapies. By working together, we ensure patients receive timely, high-quality cancer care.”

“We are excited to offer our patients expanded options for cancer treatment,” said Jeanna Knoble, MD, medical oncologist and Zangmeister managing partner. “Being an affiliate of The James Cancer Network allows us to extend specialized treatment pathways when needed, including access to clinical trials, CAR T-cell therapy, stem cell transplant evaluation and other highly specialized services. As part of The James Cancer Network, we are further strengthening our ability to serve patients where they are. We remain committed to growing our long-term relationships with referring providers in the community while creating a direct path to the specialty services available through a world-class academic center when specific patients need it. This next step allows us to build on our relationships with community colleagues while expanding access to advanced care options and maintaining strong connections to local care teams. It reinforces our commitment to delivering high-quality care rooted in the community with access to academic excellence.”

The OSUCCC – James is one of the country’s NCI-funded phase I/II clinical trial centers, so patients have access to the most innovative cancer therapies available in a clinical trial setting.

“We are proud to collaborate with OSUCCC – James,” said Steven Swart, executive vice president of practice operations at American Oncology Network. “This affiliation reflects our commitment to expanding access to innovative, evidence-based cancer care and ensuring patients across central Ohio benefit from both community-based care and academic expertise.”

As central Ohio’s only National Cancer Institute-designated Comprehensive Cancer Center, the OSUCCC – James serves as a hub within a broader network of care delivery. Through eight James Cancer Network affiliates across the state, patients gain expanded access to clinical trials, subspeciality expertise and advanced treatments, including CAR T-cell therapy, tumor-infiltrating lymphocyte (TIL) therapy and proton therapy at the OSUCCC – James.

In addition to clinical collaboration, the affiliation will support coordinated community outreach efforts and expanded medical education opportunities for physicians and care teams, further strengthening cancer care delivery across the region.

To learn more visit ZangCenter.com/JCN or call 614-347-4939.

Media Contacts

Karen Sawyer | AON and Zangmeister Cancer Center
Karen.Sawyer@aoncology.com | 541-221-1472

Amanda Harper | OSUCCC – James
Amanda.Harper2@osumc.edu | 614-685-5420

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0fe4c56b-ab29-42a5-828f-6d4a488b67b8

FAQ

What did American Oncology Network (AONC) announce about Zangmeister Cancer Center on May 21, 2026?

American Oncology Network announced that Zangmeister Cancer Center became an affiliate of Ohio State’s OSUCCC – James through The James Cancer Network. According to American Oncology Network, this affiliation expands community-based cancer care across central Ohio and links patients to academic-level expertise and advanced treatments.

How does the OSUCCC – James affiliation benefit Zangmeister Cancer Center patients (AONC)?

The affiliation gives Zangmeister patients access to more than 500 clinical trials and highly specialized cancer therapies. According to Zangmeister Cancer Center, patients can receive CAR T-cell therapy, stem cell transplant evaluation and other advanced services while staying connected to their local oncology care teams.

What advanced cancer therapies become available through the James Cancer Network for AONC’s Zangmeister patients?

Zangmeister patients gain access to CAR T-cell therapy, tumor-infiltrating lymphocyte (TIL) therapy and proton therapy at OSUCCC – James. According to Ohio State, these options are offered within an NCI-funded phase I/II clinical trial center, supporting innovative, evidence-based cancer care.

How many clinical trials are available to Zangmeister Cancer Center patients under the AONC and OSUCCC – James affiliation?

The affiliation provides access to more than 500 clinical trials across a wide range of cancers. According to OSUCCC – James, its status as an NCI-funded phase I/II clinical trial center supports timely access to innovative therapies in a clinical trial setting for central Ohio patients.

What does the James Cancer Network affiliation mean for community-based oncology care in central Ohio (AONC)?

The affiliation connects community oncology at Zangmeister with the subspecialized expertise of OSUCCC – James. According to American Oncology Network, it enhances local access to academic excellence, strengthens relationships with referring providers and supports coordinated outreach and medical education across the region.